Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Other solid neoplasm 3Tumor-Agnostic 2Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Solid Tumors 2Solid Tumours 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × brigimadlin × Other solid neoplasm × Clear all
NCT06619509 2026-04-14

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Boehringer Ingelheim

Phase 2 Active not recruiting
90 enrolled
Other solid neoplasm

Solid Tumours

NCT05372367 2026-02-03

A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

Boehringer Ingelheim

Phase 1 Completed
33 enrolled
Other solid neoplasm

Solid Tumors

NCT05613036 2025-01-22

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Boehringer Ingelheim

Phase 1 Completed
13 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡